Mebeverine HCL SR Pellets

The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration...

The objective is to develop Duloxetine DR pellets by aqueous technology. Pellets developed by aqueous technology have advantage of avoiding the use of organic solvents

Murli Krishna Pharma developed a Nano particle based premix for direct compression into tablets. The premix was developed using the following approach: 1)            Enhance the solubility of Erlotinib at near neutral pH. 2)  ...

MUPS have distinct advantages over single unit system such as multiple unit particles get distributed throughout the GI tract thereby avoiding localized accumulation. MUPS developed by aqueous technology have also advantage of avoiding the use of organic solvents.

MKPPL is the first to come up with Pellet based approach for Immune Suppressants.  Our pellet based approach reduces the variability of absorption of “LIMUS” based immune suppressants owing to smoother and uniform surface of the particles.

MKPPL have developed safe Nano particles that encapsulate micro nutrients and interact with the outermost layer of skin to enhance penetration and can be delivered through an oil platform. Infant oil massage has been a traditional practice in India. We plan to leverage this practice to implement a tech...

The Extended release pellets are the mixture of two types of pellets. Part A contains immediate release pellets as a loading dose for onset of action and Part B contains extended release pellets as a maintenance dose. These two types of pellets are blended together and the final strength of pellets is ...

MESALMINE PELLETS 70%   Physical Specifications: White to off while spherical pellets, Pellets Size: ASTM 16#80. Release specification: As per latest USP std, including additional parameters i.e. Related Substances (RS/impurities) and Microbiological (Ready To Fill si...

We are specialized in the manufacture of Pharmaceutical Pellets/ Pre-formulations/ ready to fill in capsules.

Orlistat is a tetra hydro lipstatin designed to treat obesity by preventing the absorption of fats from the human diet, thereby reducing caloric intake.

The first formulation of Paclitaxel that were marketed based on Cremaphor owing to its poor solubility in water. However the limitations in terms of particle size and the side effects of Cremaphor, this formulation is not used as widely as it was earlier especially after the advent of NAB-Paclitaxel or...

Porcine Pancreatin formulated as enteric-coated (acid-resistant) mini micro spheres within gelatin capsules. The capsules dissolve rapidly in the stomach releasing plenty of mini micro spheres, a multi dose principle which is designed to achieve good mixing with the chyme, emptying from the sto...

Murli Krishna Pharma Pvt Ltd is a young and dynamic Novel Drug Delivery Systems (NDDS) organization that provides a range of effective solutions to optimize the delivery of pharmaceutical products. Our current activities include manufacturing of pre-finished formulations i.e. Pellets, Granules and MUPS using Aqueous Based technology, Nano Particles and Transdermal Oil.

Tamsulosin HCL SR pellets is developed using an Aqueous platform and our USP lies in complying with all the US Pharmacoepial specifications. With a formulation that is in line with the Innovator product in terms of release profile, We extensively use Extrusion spheronization process besides the wurster process

Murli Krishna Pharma is one of the few companies from India who have developed Albumin bound Paclitaxel. The particle size and the encapsulation efficiency have matched with the innovator’s specifications. In Vitro Cell line studies have shown that the activity is comparable to the innovator.

Leading Manufacturer from India for Orlistat pellets. Offering a product matching the Innovator's release profile, our product does not infringe with the patent.

A Topical administration route had been chosen for the first time for Iron and Vitamins. With Minimal to Zero side effects, the absorption is almost close to 60% when compared to that of the oral route where the absorption is less than 20%. With a strong back up of clinicals on infants, this product of Murli Krishna Pharma is in the process of getting patented